Table 3.
Primary and secondary outcomes according to the development of RRT at the latest follow-up*
| RRT (n = 17) | No RRT (n = 82) | Effect estimate (95% CI) | p value | |
|---|---|---|---|---|
| Primary outcome | ||||
| Hospital mortality | 9 (52.9) | 24 (29.3) | 0.68 (0.21−2.15)a | 0.514 |
| Secondary outcomes | ||||
| ICU mortality | 9 (52.9) | 21 (25.6) | 0.56 (0.17−1.82)a | 0.338 |
| Duration of ventilation, days | 14.1 (10.0−33.0) | 14.0 (9.1−20.0) | 0.62 (0.24−1.64)b | 0.339 |
| In survivors | 28.6 (21.1−37.2) | 15.0 (9.1−19.6) | ||
| ICU length of stay, days | 15.0 (10.0−33.0) | 14.0 (10.0−20.2) | 0.62 (0.24−1.64)b | 0.339 |
| In survivors | 29.0 (22.0−37.2) | 15.0 (10.0−20.0) | ||
| Hospital length of stay | 27.0 (13.0−42.0) | 27.0 (19.0−32.0) | −c | − |
| In survivors | 39.0 (31.8−44.8) | 30.0 (23.0−34.8) |
Data are median (quartile 25–75%) or n (%). Percentages may not total 100 because of rounding. ICU, intensive care unit; CI, confidence interval; RRT, renal replacement therapy.
*
Latest follow-up at April 20, 2020.
a
Effect estimate is hazard ratio from a Cox proportional hazard model with inverse probability of treatment weighting.
b
Effect estimate is sub-distribution hazard ratio from an unadjusted Fine-Gray competing risk model with death before the event as the competing risk and with inverse probability of treatment weighting.
c
Not estimated because there is no hospital discharge in the RRT group until the latest follow-up.